651744-45-5 Purity
96%
If you have any other questions or need other size, please get a quote.
Specification
Reference: [1] Chemical and Pharmaceutical Bulletin, 2015, vol. 63, # 5, p. 341 - 353
Reference: [1] Tetrahedron Letters, 2004, vol. 45, # 11, p. 2317 - 2319
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 3, p. 693 - 698
Reference: [1]Current Patent Assignee: SYROS PHARMACEUTICALS INC - WO2018/191587, 2018, A1
Location in patent: Paragraph 0155; 0157
[2]L'Heureux, Alexandre; Thibault, Carl; Ruel, Réjean
[Tetrahedron Letters, 2004, vol. 45, # 11, p. 2317 - 2319]
[3]Current Patent Assignee: PFIZER INC - WO2009/89352, 2009, A1
Location in patent: Page/Page column 54
Reference: [1]Current Patent Assignee: IKENA ONCOLOGY INC - WO2022/51568, 2022, A1
Location in patent: Paragraph 0783
[2]Current Patent Assignee: IKENA ONCOLOGY INC - WO2022/51568, 2022, A1
Location in patent: Paragraph 0783
[3]L'Heureux, Alexandre; Thibault, Carl; Ruel, Réjean
[Tetrahedron Letters, 2004, vol. 45, # 11, p. 2317 - 2319]
[4]Current Patent Assignee: REDX PHARMA PLC - WO2016/55790, 2016, A1
Location in patent: Paragraph 00172
* For details of the synthesis route, please refer to the original source to ensure accuracy.